FDA Approves Krazati for Lung Cancer with a KRAS G12C Mutation
On December 12th, 2022, the Food and Drug Administration (FDA) approved Krazati (adagrasib) for treatment of non-small cell lung cancer (nsclc) where there is a KRAS G12C mutation. This approval is for patients who have received at least one line [...]